Atlas Trials

Endoscopic Ultrasound Radiofrequency Ablation and Immunotherapy Pembrolizumab for Locally Advanced Unresectable and Metastatic Pancreatic Duct Adenocarcinoma

Clinical trial NCT06831136 · RECRUITING

Trial details

NCT number
NCT06831136
Sponsor
The University of Texas Health Science Center, Houston
Status
RECRUITING
Phase
Phase 2
Study type
INTERVENTIONAL
Pancreatic Ductal Adenocarcinoma
Start date
2025-03-26
Primary completion
2028-01-20
Enrollment
24

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.